Brooke Army Medical Center, JBSA, Fort Sam Houston, TX, USA.
231653Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
J Intensive Care Med. 2021 Jul;36(7):818-827. doi: 10.1177/0885066620930994. Epub 2020 Jun 8.
Multidrug-resistant infections complicating combat-related trauma necessitate the use of broad-spectrum antimicrobials. Recent literature posits an association between vancomycin (VANC) and piperacillin-tazobactam (VPT) combination therapy and acute kidney injury (AKI). We examined whether therapy with VPT was associated with an increased risk of AKI compared to VANC and other broad-spectrum β-lactam antibiotics (VBL) following combat-related injuries.
Patients within the Trauma Infectious Disease Outcomes Study (TIDOS) who received ≥48 hours concomitant VPT or VBL started within 24 hours of each other were assessed. Exclusion criteria were receipt of renal replacement therapy and baseline creatinine >1.5 mg/dL. Acute kidney injury was defined by meeting any of the Risk, Injury, Failure, Loss, End Stage Renal Disease (RIFLE), AKIN, or VANC consensus guidelines criteria 3 to 7 days after therapy initiation. Variables significantly associated with AKI were used in inverse probability treatment weighting to perform univariate and subsequent logistic regression multivariate modeling to determine significant risk factors for AKI.
Sixty-one patients who received VPT and 207 who received VBL were included. Both groups had a median age of 24 years and initial median creatinine of 0.7 mg/dL. The VBL patients were more likely to have sustained blast injuries ( = .001) and received nephrotoxic agents (amphotericin [ = .002] and aminoglycosides [ < .001]). In the VBL group, AKI incidence was 9.7% compared to 13.1% in the VPT group ( = .438). Multivariate analysis identified a relative risk of 1.727 (95% CI: 1.027-2.765) for AKI associated with VPT exposure. Acute kidney injury severity generally met RIFLE criteria and was 1 day in duration. Only 1 patient had persistent renal dysfunction 30 days after therapy completion.
In this young and previously healthy, severely ill combat-injured population, VPT was associated with nearly twice the risk of AKI compared to VBL. Nevertheless, AKI was of low severity, short duration, and had high rates of renal recovery.
合并战创伤的多重耐药感染需要使用广谱抗生素。最近的文献提出,万古霉素(VANC)和哌拉西林他唑巴坦(VPT)联合治疗与急性肾损伤(AKI)之间存在关联。我们研究了与 VANC 和其他广谱β-内酰胺类抗生素(VBL)相比,VPT 治疗是否会增加与战创伤相关的 AKI 风险。
在创伤感染性疾病结局研究(TIDOS)中,评估了在开始 VPT 或 VBL 治疗的 24 小时内接受了≥48 小时的联合治疗的患者。排除标准为接受肾脏替代治疗和基线肌酐>1.5mg/dL。AKI 定义为在治疗开始后 3 至 7 天内符合任何 Risk、Injury、Failure、Loss、End Stage Renal Disease(RIFLE)、AKIN 或 VANC 共识指南标准。在单变量和随后的逻辑回归多变量模型中,使用与 AKI 显著相关的变量进行逆概率治疗加权,以确定 AKI 的显著危险因素。
纳入了 61 例接受 VPT 治疗的患者和 207 例接受 VBL 治疗的患者。两组患者的中位年龄均为 24 岁,初始肌酐中位数为 0.7mg/dL。VBL 组更有可能发生爆震伤( <.001),并且接受了肾毒性药物(两性霉素[ <.001]和氨基糖苷类[ <.001])。在 VBL 组,AKI 发生率为 9.7%,VPT 组为 13.1%( =.438)。多变量分析确定 VPT 暴露与 AKI 相关的相对风险为 1.727(95%CI:1.027-2.765)。AKI 严重程度通常符合 RIFLE 标准,持续 1 天。仅 1 例患者在治疗结束后 30 天仍存在肾功能障碍。
在这群年轻且既往健康、病情严重的战创伤患者中,与 VBL 相比,VPT 与 AKI 的风险几乎增加了一倍。然而,AKI 的严重程度较轻,持续时间较短,且肾脏恢复率较高。